

# Global Peptide Therapeutics Market & Clinical Trials Insight 2022

<https://marketpublishers.com/r/G9F04B199D0EN.html>

Date: May 2017

Pages: 1300

Price: US\$ 3,000.00 (Single User License)

ID: G9F04B199D0EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report highlights:

Fundamentals of Peptide Therapeutics

Peptide Therapeutics by Applications & Indications

Peptides Clinical Trials Insight by Phase, Indication & Company

Insight on 688 Peptide Drugs in Clinical Trials

Clinical & Patent Insight on 119 Marketed Peptides

Future Peptide Therapeutics Market Outlook

“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report gives comprehensive insight into the various clinical and non-clinical issues involved in the development of global peptide drug market. In recent years, peptides have emerged as one of the important classes of therapeutic molecules which have been developed by varied pharmaceutical and biotech companies in order to attain a targeted drug discovery for several ailments. As per report findings, there are 688 peptide drugs in clinical pipeline and more than 100 peptide based drugs commercially available in the market.

Research and development of peptide based therapeutics has gained significant momentum in past several decades due to high safety and efficacy profiles. This drives the pharmaceutical companies to invest more in this segment to come forth with competitive products for marketing. Owing to large number of diseases indications they have potential to occupy large market shares and generate significant amount of revenues. Pharmaceutical companies focused their efforts to tap this market segment by investing more funds in research and development activities. As a result, newer peptide based therapeutics are entering in global market and others are at various phases of clinical trials which are expected to get marketing approval in near future. Increased competition with drugs belonging to other categories for same disease indication is also expected to increase with time in this segment.

Peptides are used in drug development programs to provide superior pharmacological effects and alleviate patient medical condition. They have high safety and efficacy due to which they are widely accepted among physicians and patients for treatment of various ailments. In clinical practice, they are used for diabetes, various kinds of cancers, infectious diseases, cardiovascular and many other diseases indications. They could be easily modified as compared to other drug categories making them highly profitable for sponsors. Due to versatility they could be used for several medical indications leading to higher market penetration. Besides therapeutics effects, mature market give advantages related to familiarity and relatively easy marketing approval.

Peptide drugs are versatile in nature due to which they can be used for treating various life threatening diseases. Modifications to achieve superior pharmacological effect are relatively easy due to which they can be introduced in market for different diseases categories. Pharmaceutical companies can generate significant revenues in global market due to this property. Diabetes, Central Nervous System (CNS), hormonal systems, cardiovascular diseases, oncology and other diseases have effective peptide based therapeutics. Potential of generating significant revenues by these drugs by pharmaceutical companies is expected to cause increase funding in research and development segment. Market size of these drugs is expected to increase several folds in near future as more innovative drugs for multiple diseases indications would be introduced in market in coming years.

Rapidly increasing number of clinical trials reflects the unmet demand for better for peptide therapeutics for patients. Due to escalating disease incidences, it has become imperative to take necessary steps to introduce innovative peptide based therapeutics rapidly in global market. Some therapeutics like GLP-1 is expected substitute for insulin which has one of the largest market size and widespread acceptability among patients

and physicians. But pharmacological efficacy of this innovative drug is clinically equivalent to insulin with additional benefit of regulation which is not found in its counterpart. Market success rates of new peptide based therapeutics will depend on the significance of data generated during clinical trials and effectiveness of marketing strategy.

## Contents

### **1. A REVOLUTION OF PEPTIDE THERAPEUTICS**

- 1.1 Peptides as Drug Candidates
- 1.2 Necessity of Peptide Therapeutics

### **2. CUSP OF SMALL MOLECULES & PROTEINS**

- 2.1 Peptides v/s Small Molecules
- 2.2 Peptides v/s Protein Biologics

### **3. FUNDAMENTALS OF PEPTIDE THERAPEUTICS**

- 3.1 Rational Design for Novel Peptides
- 3.2 Aspects of Regulatory Approvals

### **4. PEPTIDE THERAPEUTICS BY APPLICATIONS**

- 4.1 Application of Peptides in Imaging
- 4.2 Application of Peptides in Diseases

### **5. PEPTIDE THERAPEUTICS IN METABOLIC DISORDER**

- 5.1 Prologue Metabolic Disorders
- 5.2 Approved Peptide Drugs for Metabolic Disorders
- 5.3 Market of Metabolic Peptides

### **6. PEPTIDE THERAPEUTICS IN CANCER**

- 6.1 Prologue to Cancer
- 6.2 Approved Peptide Drugs in Cancer Therapeutics
- 6.3 Market of Cancer Peptides

### **7. PEPTIDE THERAPEUTICS IN CARDIOVASCULAR**

- 7.1 Prologue to Cardiovascular Diseases
- 7.2 Approved Peptide Drugs in Cardiovascular Diseases
- 7.3 Market of Cardiac Peptides

## **8. PEPTIDE THERAPEUTICS IN HIV & INFECTIONS**

- 8.1 Prologue to Infections
- 8.2 Approved Peptide Therapeutics in Infections
- 8.3 Market of Anti-Infectious Peptides

## **9. PEPTIDE THERAPEUTICS IN CNS DISORDERS**

- 9.1 Prologue to CNS Disorders
- 9.2 Neuropeptides Drug Delivery to CNS
- 9.3 Future Market Potential

## **10. GLOBAL PEPTIDE THERAPEUTICS MARKET**

- 10.1 Prologue to the Peptide Market
- 10.2 Peptide Market by Application

## **11. GLOBAL PEPTIDE MARKET BY ADMINISTRATION**

- 11.1 Current Trends in Route of Administration
- 11.2 Current Trends over the Peptide Products

## **12. GLOBAL PEPTIDES CLINICAL TRIALS OVERVIEW**

- 12.1 Cyclic Peptides
- 12.2 Depsipeptides
- 12.3 Dipeptides
- 12.4 Glucagon-Like Peptides
- 12.5 Lipopeptides
- 12.6 Natriuretic Peptides
- 12.7 Neuropeptides Peptides
- 12.8 Oligopeptides
- 12.9 Opioid Peptides
- 12.10 Peptides
- 12.11 Peptide Hormones
- 12.12 Peptide Fragments
- 12.13 Multiple Peptides

## **13. GLOBAL PEPTIDE MARKET BY REGION**

13.1 North America

13.2 Europe

13.3 Asia

## **14. GLOBAL PEPTIDE MARKET DYNAMICS**

14.1 Favorable Parameters

14.2 Challenges

## **15. FUTURE PEPTIDE THERAPEUTICS MARKET OUTLOOK**

15.1 Future Trends in Peptide Therapeutics

15.2 Future Opportunities of Peptides Therapeutics

## **16. CYCLIC PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

16.1 Research till Preregistration

16.2 Marketed

## **17. DEPSIPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

17.1 Preclinical till Preregistration

17.2 Marketed

## **18. DIPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

18.1 Preclinical till Registered

18.2 Marketed

## **19. GLYCOPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

19.1 Preclinical till Phase-I

## **20. GLUCAGON-LIKE PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE,**

**INDICATION & COMPANY**

20.1 Resarch till Phase-III

20.2 Marketed

**21. LIPOPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

21.1 Preclinical till Phase-II

**22. NATRIURETIC PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

22.1 Preclinical till Phase-III

22.2 Marketed

**23. NEUROPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

23.1 Preclinical till Phase-III

23.2 Marketed

**24. OLIGOPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

24.1 Preclinical till Registered

24.2 Marketed

**25. OPIOID PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

25.1 Preclinical till Preregistration

25.2 Marketed

**26. PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

26.1 Research till Registered

26.2 Marketed

## **27. PEPTIDE ANTIBIOTICS CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

27.1 Research

## **28. PEPTIDE APTAMERS CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

28.1 Preclinical

## **29. PEPTIDE HORMONES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

29.1 Research till Registered

29.2 Marketed

## **30. PEPTIDE FRAGMENTS CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

30.1 Research till Preregistration

30.2 Marketed

## **31. MULTIPLE PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY**

31.1 Research till Preregistration

31.2 Marketed

## **32. COMPETITIVE LANDSCAPE**

32.1 Amgen

32.2 Amylin Pharmaceuticals

32.3 Apitope Technology

32.4 BioPartners

32.5 BiondVax Pharmaceuticals Ltd

32.6 Boehringer Ingelheim

32.7 Circassia

32.8 Corden Pharma (Peptisyntha)

32.9 Eli Lilly



- 32.10 Galena Biopharmaceuticals
- 32.11 GlaxoSmithKline
- 32.12 Hyperion Therapeutics
- 32.13 ImmunoCellular Therapeutics
- 32.14 Ipsen
- 32.15 Lonza
- 32.16 Merck
- 32.17 NovoNordisk
- 32.18 Par Pharmaceuticals
- 32.19 PeptiDream
- 32.20 Roche
- 32.21 Sanofi
- 32.22 Tarix Pharmaceuticals

## List Of Figures

### LIST OF FIGURES

- Figure 2-1: Peptides as a Cusp of Small Molecule Drug & Proteins
- Figure 2-2: Layout of Advantages of Peptide Drugs
- Figure 3-1: Classification Based over the Sources of Peptide
- Figure 3-2: Strategies for Screening of Novel peptides for Therapeutic Use
- Figure 3-3: Methods for Generating Peptide Therapeutics at Large Scale
- Figure 3-4: Whole General Concept of Manufacturing of Peptide Drugs
- Figure 3-5: Process of Peptide Therapeutics FDA Approval Path
- Figure 4-1: Diagrammatic Representation of the Peptidic Probe
- Figure 4-2: Distribution of Therapeutic Drugs Approved by FDA by Chemical Species
- Figure 5-1: Layout of Metabolic Syndrome Leading to Several Diseases
- Figure 5-2: Global - Top 10 Countries with Diabetes Burden (Million), 2030
- Figure 5-3: Obesity - Estimated Prevalence by Country (2025)
- Figure 5-4: US– GLP-1 Agonist Drugs Cost Comparison (US\$)
- Figure 5-5: Lantus – Monthly Cost Comparison by Country (US\$)
- Figure 5-6: Global - Metabolic Disorders Peptide Drug Market (US\$ Billion)
- Figure 5-7: Victoza - GLP-1 Value Market Percentage Share of Total Diabetic Care Market
- Figure 6-1: Global - All Cancer Rates Cases per 100,000 People by Top 10 Country
- Figure 6-2: Global - Cancer Peptide Therapeutics Market (US\$ Billion), 2014 & 2020
- Figure 6 3: Global - Velcade Market Sales (US\$ Billion)
- Figure 6-4: US – Velcade Sales (US\$ Billion), 2016 & 2022
- Figure 6-5: Global - Kyprolis Revenues (US\$ Billion), 2013 - 2017
- Figure 6-6: Global & US - Zoladex Sales (US\$ Million), 2016
- Figure 7-1: Global & US - Angiomax Sales (US\$ Million)
- Figure 7-2: Global - Integrilin Sales (US\$ Million), 2016
- Figure 8-1: Global - Top 10 Leading Causes of Death
- Figure 8-2: Global – HIV Prevalence among Varied Regions
- Figure 8-3: Fuzeon - Global Sales (US\$ Millions), 2016
- Figure 9-1: US - Prevalence of Alzheimer’s disease (Millions)
- Figure 10-1: Global - Peptide Drug Market (US\$ Billion), 2014-2022
- Figure 11-1: Therapeutic Peptide Based Drugs over Route of Administration
- Figure 12-1: Global – All Peptides Clinical Pipeline by Phase (%), 2017 till 2022
- Figure 12-2: Global - All Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
- Figure 12-3: Global - Cyclic Peptides Clinical Pipeline by Phase (%), 2017 till 2022
- Figure 12-4: Global - Cyclic Peptides Clinical Pipeline by Phase (Number), 2017 till

2022

Figure 12-5: Global - Depsipeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022

Figure 12-6: Global - Depsipeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 12-7: Global - Dipeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022

Figure 12-8: Global - Dipeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 12-9: Global - Glucagon-Like Peptides Clinical Pipeline by Phase (%), 2017 till 2022

Figure 12-10: Global - Glucagon-Like Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 12-11: Global - Lipopeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022

Figure 12-12: Global - Lipopeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 12-13: Global - Natriuretic Peptides Clinical Pipeline by Phase (%), 2017 till 2022

Figure 12-14: Global - Natriuretic Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 12-15: Global - Neuropeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022

Figure 12-16: Global - Neuropeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 12-17: Global - Oligopeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022

Figure 12-18: Global - Oligopeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 12-19: Global - Opioid Peptides Clinical Pipeline by Phase (%), 2017 till 2022

Figure 12-20: Global - Opioid Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 12-21: Global - Peptides Clinical Pipeline by Phase (%), 2017 till 2022

Figure 12-22: Global - Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 12-23: Global - Peptide Hormones Clinical Pipeline by Phase (%), 2017 till 2022

Figure 12-24: Global - Peptide Hormones Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 12-25: Global - Peptide Fragments Clinical Pipeline by Phase (%), 2017 till 2022

Figure 12-26: Global - Peptide Fragments Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 12-27: Global - Multiple Peptides Clinical Pipeline by Phase (%), 2017 till 2022

Figure 12-28: Global - Multiple Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

Figure 14-1: Illustration of Peptide Therapeutics Market Drivers

Figure 14-2: Major Challenges Faced by the Peptide Therapeutics

Figure 15-1: Future Trends of Peptide Therapeutics

## List Of Tables

### LIST OF TABLES

- Table 2-1: Comparative Analysis of Small Molecules & Peptide Drugs
- Table 2-2: Comparative Differentiation between Peptide & Protein Drugs
- Table 5-1: Major Approved GLP-1 Peptide Drugs for Metabolic Disorders
- Table 5-2: Layout of Insulin & its Analogs Cost in US
- Table 6-1: Approved Commercialized Peptide Cancer Drugs
- Table 7-1: Approved Peptide Drugs for Cardiovascular Diseases
- Table 8-1: Approved Drugs for Infections
- Table 9-1: Brief Characterization of Some Neuroprotective Peptides
- Table 9-2: Potential Targets for Peptide Based Therapies in CNS Disorders
- Table 11-1: List of Approved Peptide Drugs Since 2000

### COMPANIES MENTIONED

Amgen  
Amylin Pharmaceuticals  
Apitope Technology  
BioPartners  
BiondVax Pharmaceuticals Ltd  
Boehringer Ingelheim  
Circassia  
Corden Pharma (Peptisyntha)  
Eli Lilly  
Galena Biopharmaceuticals  
GlaxoSmithKline  
Hyperion Therapeutics  
ImmunoCellular Therapeutics  
Ipsen  
Lonza  
Merck  
NovoNordisk  
Par Pharmaceuticals  
PeptiDream  
Roche  
Sanofi  
Tarix Pharmaceuticals

## I would like to order

Product name: Global Peptide Therapeutics Market & Clinical Trials Insight 2022

Product link: <https://marketpublishers.com/r/G9F04B199D0EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9F04B199D0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970